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CTGF drives autophagy, glycolysis and
senescence in cancer-associated fibroblasts
via HIF1 activation, metabolically promoting
tumor growth
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Previous studies have demonstrated that loss of caveolin-1 (Cav-1) in stromal cells drives the activation of the TGFβ signaling,
with increased transcription of TGFβ target genes, such as connective tissue growth factor (CTGF). In addition, loss of
stromal Cav-1 results in the metabolic reprogramming of cancer-associated fibroblasts, with the induction of autophagy
and glycolysis. However, it remains unknown if activation of the TGFβ/CTGF pathway regulates the metabolism of cancerassociated fibroblasts. Therefore, we investigated whether CTGF modulates metabolism in the tumor microenvironment.
For this purpose, CTGF was overexpressed in normal human fibroblasts or MDA-MB-231 breast cancer cells. Overexpression
of CTGF induces HIF-1α-dependent metabolic alterations, with the induction of autophagy/mitophagy, senescence and
glycolysis. Here, we show that CTGF exerts compartment-specific effects on tumorigenesis, depending on the cell-type.
In a xenograft model, CTGF overexpressing fibroblasts promote the growth of co-injected MDA-MB-231 cells, without
any increases in angiogenesis. Conversely, CTGF overexpression in MDA-MB-231 cells dramatically inhibits tumor growth
in mice. Intriguingly, increased extracellular matrix deposition was seen in tumors with either fibroblast or MDA-MB-231
overexpression of CTGF. Thus, the effects of CTGF expression on tumor formation are independent of its extracellular
matrix function, but rather depend on its ability to activate catabolic metabolism. As such, CTGF-mediated induction
of autophagy in fibroblasts supports tumor growth via the generation of recycled nutrients, whereas CTGF-mediated
autophagy in breast cancer cells suppresses tumor growth, via tumor cell self-digestion. Our studies shed new light on
the compartment-specific role of CTGF in mammary tumorigenesis, and provide novel insights into the mechanism(s)
generating a lethal tumor microenvironment in patients lacking stromal Cav-1. As loss of Cav-1 is a stromal marker of
poor clinical outcome in women with primary breast cancer, dissecting the downstream signaling effects of Cav-1 are
important for understanding disease pathogenesis, and identifying novel therapeutic targets.
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Introduction
It is now well-established that to fully understand the
mechanism(s) driving tumor recurrence, metastasis and clinical
outcome in cancer patients, it is necessary to study the role of
the tumor microenvironment. In particular, cancer-associated
fibroblasts play a crucial role through paracrine interactions with
adjacent epithelial cancer cells.1

We and others have recently shown that a loss of caveolin-1
(Cav-1) in stromal cells is a predictor of early tumor recurrence,
lymph node metastasis, tamoxifen resistance and poor clinical
outcome in human breast cancer patients.2,3 To investigate the
downstream effects of a loss of stromal Cav-1, we isolated bone
marrow-derived stromal cells from WT and Cav-1(-/-)-null mice
and subjected them to metabolomic and proteomic analyses and
genome-wide transcriptional profiling. Interestingly, Cav-1(-/-)
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and autophagy in cancer-associated fibroblasts leads to cellular
self-digestion, promoting the release of recycled nutrients into the
tumor microenvironment, which can be used by adjacent cancer
cells as building blocks to support their anabolic growth. In support of this hypothesis, we observed that in a xenograft model,
the HIF-1α-dependent activation of autophagy in stromal cells
greatly enhanced the tumorigenicity of MDA-MB-231 breast cancer cells. On the contrary, HIF-1α activation in MDA-MB-231
cells suppressed tumor growth.8 As HIF-1α triggers autophagy in
both fibroblasts and cancer cells, these data demonstrate that the
role of autophagy in driving tumor formation is cell type- and
compartment-specific.
Other studies have shown that a loss of Cav-1 in fibroblasts
is sufficient to mediate the ligand-independent activation of
transforming growth factorβ (TGFβ).1,7 TGFβ is activated during normal wound repair9,10 and in fibrotic skin disorders.11,12
TGFβ determines fibroblast proliferation, increases extracellular matrix deposition and can also induce a reduction of extracellular matrix degradation.13 In a previous study of Cav-1(-/-)
stromal cells, we demonstrated the upregulation of 35 transcripts
associated with activated TGFβ signaling.14 In particular, one of
the most upregulated TGFβ-target genes was connective tissue
growth factor (CTGF), with a 2.2-fold induction.4 However,
it remains unknown if CTGF plays a critical role in the tumor
microenvironment.
CTGF is a TGFβ-target gene and a member of the CCN
family of secreted proteins, which consists of four conserved subdomains: an insulin-like growth factor-binding protein (IGFBP)
domain, a von Willebrand factor type C (VWC) domain, a
thrombospondin type I (TSP) repeat and a C-terminal cysteine
knot (CT) domain.15 CTGF is expressed in several cell types,
such as endothelial cells, fibroblasts and leukocytes but especially in osteoblasts and chondrocytes. CTGF is a multi-functional signaling modulator involved in a wide variety of biologic
and pathologic processes, including cell proliferation, adhesion,
migration and extracellular matrix synthesis. Furthermore,
CTGF has been identified as a pro-mitogenic and pro-angiogenic co-factor.9,16-19
While the role of CTGF in tissue fibrosis has been well studied,20 the function of CTGF in cancer pathogenesis remains controversial. Interestingly, CTGF has been identified as an oncogene
in a variety of cancer types but is considered a tumor-suppressor
gene in other contexts. CTGF overexpression is found in melanoma, sarcoma, chondrosarcoma, acute lymphoblastic leukemia
and pancreatic cancer21-25 and is associated with increased invasion, migration, the desmoplastic reaction and with chemo-resistance. However, other studies have shown that CTGF expression
inhibits the migration and invasion of ovarian,26 colorectal27 and
oral squamous cell28 carcinoma cells.
Thus, the aim of the present study was to evaluate the compartment-specific role of CTGF in breast cancer. In particular,
we aimed to explore if CTGF plays a role in the metabolic reprogramming of both cancer cells and their tumor microenvironment. To study the cell type- and compartment-specific effects of
CTGF expression, CTGF was overexpressed in fibroblasts as well
as in MDA-MB-231 breast cancer cells.

© 2012 Landes Bioscience.
Figure 1. CTGF overexpression induces an autophagy/mitophagy program in fibroblasts. (A) Fibroblasts were stably transfected with a CTGF
or Lv-105 empty vector plasmid, using a lentiviral vector approach. Total
proteins were isolated from transfected fibroblasts and analyzed by
immunoblotting to confirm CTGF expression. (B) Immunoblot analysis
shows that CTGF overexpression induces the activation of autophagy/
mitophagy in fibroblasts, as judged by increased expression levels of
BNIP3, Beclin-1, Lamp-1 and LC3, as compared with control cells. The
expression of β-actin was assessed to ensure equal protein loading.
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stromal cells showed significant metabolic alterations, with
reprogramming toward glycolysis, induction of autophagy and
oxidative stress.4 Indeed, acute knockdown of Cav-1 in fibroblasts
induces the expression of pyruvate kinase M2 (PKM2), a glycolytic enzyme sufficient to trigger aerobic glycolysis, and promotes
the generation of reactive oxygen species (ROS).5 In addition, we
demonstrated that a loss of stromal Cav-1 induces the transcription of ROS-associated genes and of hypoxia-inducible factor 1α
(HIF-1α) and NFκB target genes.5 Thus, a loss of Cav-1 in cancer-associated fibroblasts may favor tumor growth via oxidative
stress and the stromal activation of HIF-1α and NFκB.6 In a
co-culture system of normal fibroblasts and MCF7 breast cancer
cells, we demonstrated that MCF7 cells induce ROS production
and oxidative stress in adjacent fibroblasts, driving the activation
of autophagy/mitophagy and aerobic glycolysis.5,7
The induction of autophagy/mitophagy and glycolysis in stromal cells generates recycled nutrients to feed epithelial cancer
cells. Then, increased lactate production derived from glycolysis
fuels the mitochondrial metabolism of adjacent cancer cells, leading to high ATP generation in cancer cells and protection against
cell death. The induction of the catabolic processes of mitophagy
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Results
CTGF overexpression in fibroblasts
induces an autophagy/mitophagy
program. Loss of stromal Cav-1
drives oxidative stress and the
induction of autophagy/mitophagy
in the tumor stroma,5,7,29 leading to
the generation of recycled nutrients
that can be used by adjacent anabolic epithelial cancer cells.5,29 We
have previously demonstrated that
a loss of stromal Cav-1 induces the
ligand-independent activation of the
TGFβ pathway7 and that Cav-1(-/-)
Figure 2. Fibroblasts overexpressing CTGF show the induction of glycolysis. (A) Immunoblot analysis
stromal cells show the upregulation
demonstrates that fibroblasts overexpressing CTGF display the increased expression of several enzymes
of 35 transcripts associated with
involved in glycolysis (Enolase-1, LDH-A, LDH-B and LDH-C), relative to empty vector control cells. β-actin
activated TGFβ signaling, includwas used to assess equal protein loading. (B) An L-lactate assay was performed on cell culture media to
ing the TGFβ target gene CTGF.14
confirm the functional role of the increased expression of the glycolytic enzymes. In fibroblasts overexTo investigate if CTGF plays a
pressing CTGF, L-lactate production is significantly increased by 20%, as compared with the empty vector
control.
role in breast tumorigenesis, CTGF
was stably overexpressed in stromal
fibroblasts (Fig. 1A). Empty vector (Lv-105) control fibroblasts were generated in parallel. Then,
Consistent with this “paracrine” metabolite hypothesis, we
CTGF overexpressing fibroblasts were analyzed by immunob- have previouosly shown that treatment with L-lactate is sufficient
lot blot analysis with a panel of autophagy/mitophagy markers. to induce mitochondrial biogenesis in breast cancer epithelial cells
Figure 1B shows that CTGF overexpression induces the increased and can functionally enhance their metastastic potential.5,29,31,32
expression of LC3 and Beclin-1 (proteins involved in the formaCTGF-induced activation of autophagy/mitophagy and glytion and maturation of auto-phagosomes), Lamp-1 (a protein colysis is HIF-1α-dependent. Our previous studies have demassociated with auto-lysosomes and lysosomes) and BNIP3 (a onstrated that a loss of stromal Cav-1 causes an accumulation
mitophagy marker whose expression leads to reductions in mito- of ROS and the activation of HIF-1α, mimicking a constitutive
chondrial mass and respiration).30 Therefore, CTGF expression pseudo-hypoxic state.14 It is well-established that increased ROS
is sufficient to induce autophagy and mitophagy in fibroblasts, levels stabilize HIF-1α expression.33 In order to assess if CTGF
downstream from a loss of stromal Cav-1.
overexpression in fibroblasts induces a pseudo-hypoxic condition,
CTGF overexpression in fibroblasts induces glycolysis. we first evaluated the expression of HIF-1α. Figure 3A shows
Increased BNIP3 expression downregulates mitochondrial mass that CTGF-overexpressing fibroblasts display increased levels of
and respiration by increasing the rate of mitophagy (mitochon- HIF-1α compared with control empty vector cells. In addition,
drial autophagy), thus compromising ATP production.30 We a significant increase in ROS production was observed in fibrospeculated that CTGF-mediated increases in BNIP3 expression blasts overexpressing CTGF (Fig. 3B) relative to control cells,
may lead to activation of glycolysis, to compensate for reduced indicating that CTGF overexpression in fibroblasts does induce a
mitochondrial function. Figure 2A shows that CTGF over- “pseudo-hypoxic” state.
expression drives elevated expression of lactate dehydrogenase
HIF-1α is a crucial transcription factor for the expression of
(LDH) -A, -B and -C, the glycolytic enzymes that convert pyru- glycolytic enzymes34 and autophagic proteins.35 To determine
vate into L-lactate. The induction of aerobic glycolysis was fur- if the CTGF-mediated induction of glycolysis and autophagy
ther validated by the increased expression of Enolase 1, another is HIF-1α-dependent, fibroblasts overexpressing CTGF were
enzyme in the glycolytic pathway.
treated with the HIF-1α inhibitor echinomycin. Echinomycin
To evaluate the functional role of increased expression of these blocks the binding of HIF-1α to DNA, thereby inhibiting its tranglycolytic enzymes, we determined the L-lactate content of the scriptional action. Note that echinomycin treatment decreases
fibroblast cell culture media. Figure 2B shows that CTGF fibro- HIF-1α expression (Fig. 4A) and greatly reduces the expression
blasts display a significant 20% increase in overall L-lactate levels, levels of autophagy (BNIP3, Lamp-1 and LC3, Fig. 4B) and
as compared with control fibroblasts. Increased L-lactate produc- glycolysis markers (Enolase 1, LDH-A and LDH-C, Fig. 4C).
tion in stromal cells could stimulate, by a paracrine mechanism, These results clearly indicate that the activation of autophagy,
the conversion of lactate into pyruvate in adjacent breast cancer mitophagy and glycolysis in fibroblasts overexpressing CTGF is
epithelial cells. Then, pyruvate would be used as a substrate for mediated by HIF-1α stabilization.
the TCA cycle to promote the oxidative mitochondrial activity
CTGF overexpression drives cellular senescence in fibroof cancer cells.
blasts. Several studies have reported that increased intracellular

© 2012 Landes Bioscience.
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development, we employed a mouse xenograft model consisting
of MDA-MB-231 breast cancer cells co-injected with CTGF or
control fibroblasts in the flanks of nude mice. After 4 weeks, mice
were sacrificed, and tumor weight and volume were measured.
Remarkably, CTGF overexpression in fibroblasts induces an
increase of 2-fold in tumor weight and of 2.6-fold in tumor volume, compared with control cells (Fig. 6A). Our previous studies have demonstrated that the autophagic stroma is sufficient to
drive tumor development without increased neo-vascularization.
Thus, we evaluated tumor vascularity using immuno-staining
with antibodies directed against CD31. Figure 6B shows a significant reduction of angiogenesis in CTGF tumors, indicating
that CTGF favors breast cancer growth independently of angiogenesis but more likely via the metabolic reprogramming of the
tumor stroma.
It is well known that CTGF stimulates extracellular matrix
deposition and activity.38,39 The extracellular matrix activates a
variety of signals, which directly influence the growth, migration
and differentiation of cells participating in virtually every state
of breast cancer pathogenesis. To investigate if the extracellular
matrix plays a key role in tumor development in our system, we
next evaluated the expression of Type I Collagen and Tenascin C
by immunohistochemistry in tumor xenografts. As predicted, the
expression levels of both Type I Collagen and Tenascin C were
elevated in tumors grown in the presence of CTGF-expressing
fibroblasts, as compared with tumors grown with vector-alone
control fibroblasts (Fig. 6C). These data suggest that CTGF
could also favor tumor growth via the induction of extracellular
matrix deposition.
CTGF-activated fibroblasts increase the mitochondrial
activity of adjacent MDA-MB-231 cells. To experimentally
evaluate if increased lactate production in fibroblasts stimulates the mitochondrial metabolism of adjacent cancer epithelial cells, we evaluated the expression of ATPase-Inibitor
Factor 1 (ATPase-IF1) in a co-culture system of fibroblasts and
MDA-MB-231 cells. ATPase-IF1 is an endogenous inhibitor of
the mitochondrial ATP synthase, leading to reduced mitochondrial activity. It is known that silencing of ATPase-IF1 activates
oxidative phosphorylation. Figure 7 shows that ATPase-IF1
expression is decreased in MDA-MB-231 cells co-cultured
with CTGF fibroblasts, as compared with MDA-MB-231 cells
grown with control fibroblasts. These results indicate that CTGF
expression in fibroblasts stimulates the mitochondrial activity of
adjacent cancer cells, in a paracrine way, likely via the generation
of high L-lactate levels.
MDA-MB-231 cells overexpressing CTGF show an increase
in autophagy and oxidative stress. To evaluate if the role of
CTGF in tumorigenesis is compartment-specific, we overexpressed CTGF in MDA-MB-231 cells (Fig. 8A). We next investigated whether CTGF also induces autophagy/mitophagy in
epithelial cancer cells. Immunoblot analysis demonstrated that
MDA-MB-231 cells overexpressing CTGF show the upregulation of several autophagy/mitophagy markers under basal condition (BNIP3, Lamp-1 and cathepsin B) (Fig. 8B) or upon
nutrient-starvation (Beclin-1 and LC3) (Fig. 8C), indicating that
CTGF can activate autophagy also in breast cancer epithelial

© 2012 Landes Bioscience.
Figure 3. CTGF overexpression in fibroblasts induces a pseudo-hypoxic
phenotype. (A) CTGF- and Lv-105 fibroblasts were analyzed by immunoblotting with antibodies against HIF-1α. Note that HIF-1α levels
are augmented in CTGF fibroblasts, suggesting that CTGF induces a
pseudo-hypoxic state. Two different exposures are shown. β-actin was
used to assess equal protein loading. (B) To evaluate if CTGF expression
drives oxidative stress, we performed a ROS assay. CTGF overexpression
induces a 20% increase in ROS production, as compared with control
cells. p < 0.05.

Do not distribute.

ROS is involved in induction of senescence. In addition, recent
evidence suggests that autophagy may also mediate the acquisition of a senescent phenotype.36,37 To verify if CTGF expression
induces a senescent phenotype in fibroblasts, we next analyzed
the expression of genes implicated in senescence by immunoblotting. Figure 5A shows that CTGF overexpression drives the
upregulation of p21(WAF/CIP1) and p16(INK4A), both inducers of cell cycle arrest. However, no changes were observed in
p19(ARF) protein expression. Conversely, CTGF induces an
increase of Cyclin D1 expression, likely a compensatory response
to senescence. To independently assess if CTGF induces a senescent phenotype, we next performed a β-galactosidase (β-Gal)
activity assay by flow cytometry (Fig. 5B) and a β-Gal staining
assay (Fig. 5C). Figure 5B shows that CTGF expression increases
β-Gal activity, as judged by increased numbers β-Gal-positive
cells and increased mean intensity. Similarly, conventional β-Gal
staining is augmented in CTGF fibroblasts as compared with
control fibroblasts (Fig. 5C), confirming the ability of CTGF to
trigger a senescence phenotype.
CTGF overexpression in fibroblasts increases breast cancer growth independently of angiogenesis. To evaluate if
CTGF expression in fibroblasts plays a role in breast cancer
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cells. However, no changes in L-lactate production were observed
in MDA-MB-231 cells overexpressing CTGF (data not shown).
Since we demonstrated that CTGF induces autophagy in fibroblasts via HIF-1α (Fig. 3), we evaluated if the same mechanism
operates in MDA-MB-231 cells. Although HIF-1α expression
is only slightly increased in MDA-MB-231 cells overexpressing
CTGF (Fig. 8D), a significant 20% increase in ROS production
in MDA-MB-231 cells overexpressing CTGF was observed as
compared with control cells (Fig. 8E). Therefore, we believe that
the CTGF induction of autophagy also depends on increased oxidative stress in breast cancer cells. Thus, we conclude that CTGF
induces an autophagic program in both cell types, fibroblasts and
MDA-MB-231 cells, by inducing oxidative stress, HIF-1α activation and a “pseudo-hypoxic” phenotype.
CTGF overexpression does not modulate the expression of
senescence markers in breast cancer cells. In order to understand if CTGF activate the same processes activated in fibroblasts
in epithelial breast cancer cells, we evaluated the expression of
proteins involved in cell cycle regulation. Figure 9 demonstrates
that CTGF overexpression in MDA-MB-231 cells does not
induce markers of senescence. Indeed, no significant changes
were detected in p16(INK4A), p19(ARF) and Cyclin D1 expression levels, whereas p21(WAF1/CIP1) was undetectable.
CTGF overexpression in breast cancer cells inhibits tumor
growth. To investigate the effects of CTGF overexpression in
breast cancer cells in vivo, CTGF-MDA-MB-231 and control
MDA-MB-231 cells were injected into the flanks of athymic
nude mice. Surprisingly, Figure 10A shows that after 3 weeks,
CTGF overexpression caused a nearly 3-fold reduction in tumor
growth. Also in this context, we did not detect any differences
in tumor neo-vascularization, as assessed by quantification of
CD31-positive vessels (Fig. 10B). These results clearly indicate
that CTGF plays a compartment- and cell type-specific role during tumor formation and exerts opposing effects depending on
which cell type expresses it.
Finally, to evaluate the role of extracellular matrix deposition
in CTGF-mediated tumorigenesis, we evaluated the expression of
Type I Collagen and Tenascin C in MDA-MB-231 tumor xenografts. Interestingly, the expression levels of Type I Collagen and
Tenascin C are increased in tumors formed by MDA-MB-231
cells overexpressing CTGF, relative to control tumors (Fig. 10C).
These results indicate that in our model, the role of CTGF in
tumorigenesis is independent on its role in extracellular matrix
remodeling. In fact, we observed increased extracellular matrix
deposition in tumors both when CTGF was expressed by cancer
cells and by fibroblasts, despite the fact that the CTGF effects on
tumor growth are just the opposite.
Thus, we speculate that in our experimental system, CTGF’s
effects are likely due to its intracellular action and not to its
extracellular action. The cells overexpressing CTGF undergo
metabolic reprogramming and become more autophagic. The
induction of CTGF-mediated autophagy in epithelial tumor
cells will cause self-digestion and inhibition of tumor growth.
Conversely, the induction of CTGF-mediated autophagy in
tumor fibroblasts will generate building blocks for the anabolic
growth of cancer cells.

© 2012 Landes Bioscience.
Do not distribute.
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Figure 4. The activation of autophagy and glycolysis in CTGF fibroblasts is HIF-1α-dependent. To evaluate if the activation of autophagy
and glycolysis of CTGF fibroblasts is HIF-1α dependent, CTGF fibroblasts
were treated with the HIF-1α inhibitor echinomycin (5–10 ng/ml) or
vehicle alone (DMSO) for 24 h. Western blot analysis demonstrates that
echinomycin treatment reduces the expression of (A) HIF-1α, (B) mitophagy (BNIP3) and autophagy (Lamp-1 and LC3) markers, and (C) glycolytic enzymes (Enolase 1, LDH-A and LDH-C). Equal loading control
was assessed using β-actin. These results indicate that CTGF expression
enhances autophagy/mitophagy and glycolysis in a HIF-1α-dependent
manner.

Discussion
Previous studies have demonstrated that a loss of Cav-1 in stromal
cells induces the ligand-independent activation of the TGFβ pathway,7,40-42 with the increased transcription of the TGFβ target gene
CTGF.1,4,14,43 It is now well known that CTGF induces tissue fibrosis, and that alterations in the extracellular matrix influence tumor
growth and clinical outcome.21,44 It has also been demonstrated
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Figure 5. CTGF overexpression in fibroblasts induces a senescence phenotype. (A) Immunoblot analysis performed on control and CTGF overexpressing fibroblasts demonstrates that CTGF expression induces the upregulation of p21 (CIP1/WAF1) and of p16Ink4A, both inhibitors of cell cycle progression. No changes were detected for p19 expression levels. Conversely, CTGF expression also induces the upregulation of cyclin D1, probably as a
compensatory response against senescence. Equal loading was assessed using β-actin. (B) A β-galactosidase assay was performed by FACS analysis
on control and CTGF overexpressing fibroblasts. The number of β-Galactosidase-positive cells (left) and the β-galactosidase intensity mean (right) are
both increased in CTGF overexpressing fibroblasts. (C) Conventional β-galactosidase staining was also performed on control and CTGF overexpressing
fibroblasts to independently confirm that CTGF overexpression induces senescence. Note that CTGF fibroblasts have intense blue staining, indicative
of increased β-galactosidase activity.

that a loss of stromal Cav-1 induces the metabolic reprogramming
of cancer-associated fibroblasts with the induction of glycolysis and
autophagy. However, it remains unknown if the activation of the
TGFβ/CTGF pathway plays a role in the metabolic reprogramming of stromal cells induced by a loss of stromal Cav-1.
Therefore, the purpose of this study was to investigate if the
TGFβ-target gene CTGF plays a role in the metabolic remodeling of the tumor microenvironment. In particular, we aimed to

www.landesbioscience.com

study if the cell type-specific expression of CTGF differentially
affects tumor development.
The role of CTGF in breast cancer remains controversial.
Elevated CTGF mRNA levels were found in human invasive
ductal carcinomas and mouse mammary tumors and were confined to the fibrous tumor stroma.44 In another breast cancer
study, overexpression of CTGF was positively associated with age,
tumor size, stage and lymph node metastasis.45 Mechanistically,
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Figure 6. CTGF overexpression in fibroblasts promotes tumor growth. To evaluate the effects of CTGF on tumor development in vivo, CTGF fibroblasts
or control fibroblasts were co-injected with MDA-MB-231 cells subcutaneously in nude mice. (A) The xenograft model shows that fibroblasts overexpressing CTGF promote tumor growth, as demonstrated by increased tumor weight and tumor volume (respectively 2 and 2.6-fold), compared with
Lv-105 control fibroblasts. n = 10; p-values are as indicated. (B) To investigate if CTGF promotes angiogenesis, tumor xenografts were immuno-stained
with CD31 antibodies. Surprisingly, quantification of CD31-positive vessels reveals a significant reduction in angiogenesis in CTFG-tumors, indicating
that CTGF stimulates tumor growth independently of angiogenesis. (C) To evaluate the role of extracellular matrix deposition in the CTGF-mediated
tumor growth, we performed immunohistochemistry analysis on tumor xenografts with antibodies against Type I Collagen and Tenascin C. Note that
tumors with CTGF-overexpressing fibroblasts show higher levels of Type I Collagen and Tenascin C.

the tumor-promoting role of CTGF is supported by data showing
that CTGF enhances tumor cell migration and angiogenesis46
and confers drug resistance.47,48 Conversely, other studies have
indicated that CTGF may act as a tumor suppressor and have
reported that low levels of CTGF are associated with increased
metastasis and poor prognosis in breast cancer patients.49 For
example, Hishikawa et al. demonstrated that forced overexpression of CTGF in MCF7 cells induces apoptosis.50
In our current studies, we propose a novel viewpoint to explain
the controversial role of CTGF in breast cancer. Our data clearly
indicate that CTGF exerts compartment-specific actions, and
that its effects on tumor growth are opposite depending on the
cell type producing CTGF. In fact, surprisingly, overexpression
of CTGF in breast cancer epithelial cells inhibits tumor growth,
but the opposite, tumor-promoting effect was observed when
CTGF is overexpressed in the tumor fibroblast compartment.
We show for the first time that the overexpression of CTGF
drives the induction of autophagy in both cell types, fibroblasts

2278

and breast cancer cells. Thus, CTGF-induced autophagy in
fibroblasts can drive stromal cell digestion, leading to the release
of chemical building blocks into the tumor microenvironment.
These nutrients could be used as fuel for the anabolic growth of
breast cancer cells, driving increased tumor mass independently
of angiogenesis. Furthermore, we show that CTGF overexpression in stromal cells triggers the induction of glycolysis. The final
product of glycolysis, L-lactate, could act in a paracrine way on
breast cancer cells. Increased L-lactate uptake by breast cancer
cells could activate LDH in cancer cells. At high lactate concentrations, LDH converts L-lactate into pyruvate, which is a substrate of the Krebs cycle, driving an increase in mitochondrial
metabolic activity. Consistent with this hypothesis, we detected
reductions in ATPase-IF1 expression in MDA-MB-231 cells
co-cultured with CTGF fibroblasts compared with the control
fibroblasts. Mechanistically, we show that the CTGF-mediated
induction of autophagy occurs via increased oxidative stress and
HIF-1α stabilization. Our results are consistent with previous
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Figure 7. CTGF fibroblasts greatly decrease the expression of ATPaseIF1 in adjacent MDA-MB-231 cells. To verify if CTGF fibroblasts exert
any paracrine effects on tumor cells, GFP-positive MDA-MB-231 cells
were co-cultured with CTGF fibroblasts or control fibroblasts for 3 d.
Cells were then immuno-stained with antibodies against ATPase-IF1 (an
endogenous inhibitor of the mitochondrial ATP synthase, RED). Nuclei
were stained with DAPI (BLUE). Note that fibroblasts overexpressing
CTGF reduce the levels of ATPase-IF in adjacent MDA-MB-231 cells (GFP).
The white stars mark the nuclei of MDA-MB-231 cells. These results
indicate that CTGF fibroblasts increase the mitochondrial activity in
adjacent breast cancer cells, by reducing ATPase-IF expression.

homolog of the yeast ATG1 is essential for the initial building
of the autophagosome, is highly expressed in senescent cells,
and that ULK-3 overexpression induces autophagy and senescence. Furthermore, the knockdown of ATG5 or ATG7 reduces
β-galactosidase activity, the most widely used marker of senescence.37 Inhibition of autophagy delays the senescence phenotype. Thus, the induction of autophagy in fibroblasts promotes
the acquisition of the senescent phenotype.37 Recently, a new
mechanism by which autophagy can lead to pre-mature senescence, has been proposed. Goligorsky et al. have demonstrated
that stress-induced lysosomal membrane permeabilization drives
the release of cathepsin B in the cytosol. Cathepsin B is a lysosomal cysteine protease, which induces SIRT1 depletion leading
to autophagy-induced premature senescence.36 Thus, autophagy
and senescence may be part of the same physiological process,
known as the autophagy-senescence transition (AST) (Fig. 11).
Cellular senescence is a reversible process that limits proliferation of cells at risk for neoplastic transformation and contributes
to aging.53-56 On the other hand, although the mechanisms have
not been fully elucidated yet but are likely to contrast aging, the
induction of senescence leads to the secretion of several mitogenic
substances, including growth factors, cytokines and extracellular
matrix components,53,57 that alter the tumor microenvironment
and favor tumor growth.58
In our study, we show for the first time that CTGF has the
ability to induce senescence. Interestingly, CTGF-mediated
induction of senescence is cell-type specific, as it occurs only in
fibroblasts but not in breast cancer cells. It might be that the induction of senescence in fibroblasts could constitute an additional
mechanism through which CTGF overexpression in stromal cells
drives tumor growth. Although the molecular mechanism(s) that
link autophagy with senescence are still unclear, we propose that
systemic induction of autophagy and increased protein turnover
could lead stromal cells to establish a senescent-like phenotype to
protect them from further self-digestion.
Our results indicate that the tumor-promoting effects of
CTGF may be independent of its well-known role in extracellular
matrix remodeling. We unexpectedly observed that CTGF has
opposite effects when it is produced by stromal cells or by breast
cancer cells. This suggests that the CTGF effects are not due
to its extracellular secretion; otherwise, we should observe the
same results, independently of the cell type producing CTGF.
Thus, our data clearly indicate that CTGF acts via an intracellular mechanism, likely through the metabolic reprogramming of the CTGF-producing cells. In support of this notion,
we observed increased extracellular matrix deposition in tumor
xenografts generated by CTGF-MDA-MB-231 cells and by
CTGF-fibroblasts. Indeed, we observed increased extracellular
matrix, which is usually considered a marker of tumor aggressiveness, in the CTGF-MDA-MB-231 xenogafts as well when the
tumor mass was reduced. These data demonstrate that CTGF
can still be secreted, but that the main CTGF tumor-promoting
effects are due to its ability to drive metabolic reprogramming
within cells. This is the first time that CTGF has been shown to
modulate the metabolic status of stromal cells within the tumor
microenvironment.
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studies showing that CTGF induces HIF-1α upregulation.51
However, the mechanism(s) by which CTGF induces HIF-1α
activation is currently unknown.
Conversely, we show that forced CTGF overexpression in
breast cancer cells inhibits tumor growth. We demonstrate that
CTGF overexpression in epithelial breast cancer cells induces
autophagy. Activation of autophagy in cancer cells increases
tumor cell self-digestion, with a consequent decrease in tumor
mass. Mechanistically, we propose that CTGF overexpression
leads to increased oxidative stress, which, in turn, stabilizes
HIF-1α. In fact, we have previously demonstrated that HIF-1α
activation in breast cancer cells drives the induction of autophagy
and inhibits tumor growth.8
Several studies have reported that increased intracellular ROS
is involved in the induction of senescence. Two mechanisms have
been proposed to explain ROS action on senescence. The first
possibility is that ROS can lead to random damage to cellular
components, thus acting as a non-specific senescence mediator. For example, an increase in ROS levels causes DNA damage, leading to activation of p53, which, in turn, drives cell cycle
arrest via induction of p21. The second explanation is that ROS
can function as messenger molecules that activate specific redoxdependent targets, and those could induce senescence.52
Recent evidence also links autophagy to cellular senescence.
In particular, it has been demonstrated that ULK-3, the human
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In conclusion, we propose a new compartment-specific role
for CTGF in tumor formation, which is mediated via intracellular metabolic rearrangements. The overexpression of CTGF
in breast cancer epithelial cells leads to autophagy activation,
tumor cell digestion and inhibition of tumor growth. On the
other hand, overexpression of CTGF in fibroblasts similarly
drives the induction of autophagy, but in this case, enhances
the release of recycled chemical building blocks into the tumor
microenvironment, which can be used as “fuel” by anabolic
tumor cells. Finally, the overexpression of CTGF drives a senescence phenotype in fibroblasts, which may further promote
tumor growth.
Materials and Methods
Materials. Antibodies were as follow: CTGF (6B13) (Santa
Cruz, sc-101586); β-Actin, (Sigma-Aldrich, A5441); Beclin-1
(Novus Biologicals, NBP1-00085); BNIP3 (Abcam, ab10433);
Cathepsin B (FL-339) (Santa Cruz, sc-13985); Lamp-1 (E-5)
(Santa Cruz, sc-17768); LC3 (Abcam, ab48395); Enolase 1
(Cell Signaling, 3810); LDH-A (Cell Signaling, 2012); LDH-B
(Sigma-Aldrich, AV48210); LDH-C (Sigma-Aldrich, AV53602);
HIF-1α, (BD Transduction Laboratories, 610959); p21 (H-164)
(Santa Cruz, sc-756); p19 (DCS-240) (Santa Cruz, sc-53639);
p16 (H-156) (Santa Cruz, sc-759); cyclin D1 (Thermo Scientific,
MS-210); ATPase-IF1 (Abcam, ab811061); Tenascin C (Leica
Microsystems, NCL-TENAS-C); and Type-I-Collagen (Cell
Sciences, PS065).
Cell culture. GFP-positive MDA-MB-231 breast cancer
cells (gift of Dr. Fatatis, Drexel University) and human foreskin
immortalized fibroblast (hTERT-BJ1, Clontech) were grown in
DMEM supplemented with 10% fetal bovine serum (FBS) and
PS (100 units/mL penicillin, 100 μg/mL streptomycin). Cells
were maintained at 37°C, in a 5% CO2 incubator. Starvation
was performed using Hank’s Balanced salt solution (HBSS)
supplemented with 40 mM Hepes and 1% PS. For the echinomycin-related experiments, cells were treated with 5 or 10 ng/ml
echinomycin (Enzo life Sciences) dissolved in DMSO for 24 h.
For co-culture experiments, fibroblasts and MDA-MB-231 cells
were plated at a ratio 5:1 on glass coverslips in 12-well plates in
complete media. After 24 h, the media was changed to DMEM
with 10% NuSerum (BD Biosciences). Cells were maintained in
co-culture for 3 d.
Lenti-viruses. Lentiviral plasmids, packaging cells and
reagents were from Genecopoeia. Lenti-viruses were prepared by
transfection of 293Ta packaging cells. For this purpose, 1.7 million 293Ta cells were seeded in 10-cm plates. After 48 h, 293Ta
cells were transfected with the lentiviral plasmids EX-NEG-Lv105
(Empty Vector) and EX-A0312-Lv105 (encoding CTGF) using
EndoFectin. After 48 h, the viruses were collected, centrifuged
and filtered. Target cells (fibroblasts or MDA-MB-231 cells)
were infected with the viruses and then selected with puromycin
(1.5 μg/ml for fibroblasts and 2 μg/ml for MDA-MB-231 cells).
Immunoblot analysis. Cells were scraped into lysis buffer containing 10 mM TRIS-HCl pH 7.5, 150 mM NaCl,
1% Triton X-100 and 60 mM N-octyl-glucoside supplemented
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Figure 8. MDA-MB-231 cells overexpressing CTGF display the induction
of autophagy/mitophagy, with HIF-1α activation. To study if CTGF expression has any compartment-specific effects, CTGF was overexpressed
in MDA-MB-231 cells. (A) Immunoblot analysis was performed on total
protein lysates to confirm CTGF overexpression. (B and C) MDA-MB-231
cells overexpressing CTGF show activation of an autophagy/mitophagy
program. Immunoblot analysis on CTGF- and control-MDA-MB-231
cells reveals that CTGF significantly increases the expression levels of
several proteins involved in mitophagy (BNIP3) and autophagy (Lamp-1,
Beclin-1, cathepsin B and LC3) under (B) basal condition or (C) after 2 h
of nutrient starvation. (D) Immunblot analysis of total protein lysates
from control and CTGF-MDA-MB-231 cells shows that CTGF expression
induces the activation of HIF-1α in MDA-MB-231 cells. Two exposures
are shown. For all, β-actin was used as control for equal protein loading. (E) ROS assay performed on control- and CTGF-MDA-MB-231 cells
reveals that CTGF expression induces a 20% increase in ROS production.

with protease (Roche Diagnostics) and phosphatase (Sigma)
inhibitor cocktails. After rotating for 40 min, samples were centrifuged 10 min at 13,000x g at 4°C, and the supernatants were
collected. For nuclear proteins, RIPA buffer (50 mM TRIS-HCl
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Figure 9. Overexpression of CTGF in MDA-MB-231 does not induce
senescence. Protein lysates from Lv-105 and CTGF-MDA-MB-231 cells
were analyzed by immunoblotting with antibodies against cell cycle
proteins. No differences in p16, p19 and cyclin D1 expression levels were
detected, while p21 was undetectable. β-actin was used as control for
equal loading.

pH 7.5, 150mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate,
0.1% SDS plus protease and phosphatase inhibitors) was used.
After lysis, cells were sonicated and centrifuged at 12,000x g for
10 min at 4°C to pellet insoluble debris. Protein concentrations
were evaluated with BCA kit (Pierce). To detect HIF-1α, cells
were lysed in Urea Buffer (6.7 M urea, 10% glycerol, 1% SDS,
10 mM TRIS-HCl pH 6.6, 1% Triton X-100 containing protease
and phosphatase inhibitors). Cells were homogenized, incubated
on ice for 10 min and centrifuged at 12,000x g for 10 min at 4°C.
Protein content was determined by Bradford assay (BioRad).
Proteins were separated by SDS-PAGE (10 to 15% acrylamide)
and transferred to a nitrocellulose membrane. After blocking in
5% milk, membranes were incubated with primary antibodies,
followed by incubation with peroxidase-coupled secondary antibodies. Bound antibodies were detected using enhanced chemiluminescence substrate (Thermo Scientific).
Lactate assay. 105 cells were plated into 12-well plates in
complete media. After 24 h, the media was changed to DMEM
containing 2% FBS. After 48 h, the media was collected, and
the lactate concentration was measured using the EnzyChromTM
L-Lactate Assay Kit (cat #ECLC-100, BioAssay Systems) according to the manufacturer’s instructions. The L-lactate concentration was normalized to the cellular protein content per well.
ROS assay. Cells were seeded in 12-well plates in complete
media. The next day, the media was changed to DMEM containing 10% NuSerum and 1% PS. ROS assay was performed after
48 h. Fibroblasts were incubated with 10 μM CM-H2DCFDA
(Invitrogen, C6827) for 15 min at 37°C. Then, cells were washed
with PBS and incubated in complete media for 15 min at 37°C.
GFP-positive MDA-MB-231 cells were incubated with CellROX
Deep Red Reagent (Invitrogen, C10422) at a final concentration
of 5 μM in complete media for 30 min at 37°C. To evaluate ROS
content, cells were washed, trypsined, resuspended in HBSS and
analyzed by flow-cytometry.
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Figure 10. CTGF overexpression in breast cancer cells inhibits tumor
growth. (A) Lv-105- and CTGF-MDA-MB-231 cells were injected subcutaneously in nude mice. Tumors were then harvested after 3 weeks.
Surprisingly, CTGF overexpression in MDA-MB-231 cells induces a nearly
3-fold reduction in tumor growth, as compared with empty vector
controls. n = 10, p-values are as indicated. (B) CD31 staining and quantification on tumor xenografts shows no differences in tumor neo-vascularization. (C) Tumor xenografts were immunostained with antibodies
against Type I Collagen and Tenascin C. Interestingly, the expression of
Type I Collagen and Tenascin C are greatly increased in MDA-MB-231
tumors with CTGF overexpression, although tumor size is decreased.
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Senescence-associated β-galactosidase staining. To detect
β-galactosidase, the senescence β-Galactosidase Staining Kit
(Cell Signaling 9860) was used. Cells were plated into 6-well
plates in complete media; after 24 h, the media was changed to
DMEM 10% NuSerum. After 48 h, cells were washed with PBS
and fixed for 15 min at room temperature with fixative solution
(2% formaldehyde, 0.2% glutaraldehyde in PBS). Afterwards,
cells were washed two times with PBS and incubated over night
at 37°C in a dry incubator without CO2 with the β-galactosidase
staining solution. Then, cells were observed under a microscope.
Senescence-associated β-galactosidase activity by flow
cytometry. The senescence β-Galactosidase Activity Kit
(Invitrogen, F1930) was used according to the manufacturer’s
instructions. Briefly, cells were seeded in 6-well plates in DMEM
supplemented with 10% FBS and 1% PS. After 24 h, the media
was changed to DMEM with 10% NuSerum. After 48 h, cells
were trypsinezed, centrifuged and counted. Then, cells were resuspended with staining media to obtain 107 cells/mL, and 100 μl
of samples were transferred to flow cytometer tubes and placed
on ice. 100 μl of pre-warmed FDG solution (2 mM Fluorescein
β-D-galactopyranoside) was added to the pre-warmed cells.
Tubes were placed in the 37°C water bath for exactly 1 min. The
reaction was stopped by adding ice-cold staining media. Cells
were analyzed by flow cytometry.
Animal studies. All in vivo studies were performed under
National Institutes of Health (NIH) guidelines and were
approved by the Institutional Animal Care and Use Committee
(IACUC) of Thomas Jefferson University. Briefly, CTGF fibroblasts or control fibroblasts (300,000 cells) were co-injected with
MDA-MB-231 (1 million cells) in the flanks of athymic NCr
nude mice (NCRNU; Taconic Farms; 6–8 weeks of age). In other
experiments, CTGF-MDA-MB-231 or control MDA-MB-231
(1 million cells) were injected in the flank of nude mice. Tumor
size and weight was recorded over a 2–4 week period. Tumors
were dissected out to determine weight and size using calipers.
Tumor volume was calculated using the formula (x 2y)/2, where
x and y are the short and long tumor dimensions, respectively.
Tumors were either fixed with 10% formalin or flash-frozen in
liquid nitrogen-cooled isopentane.
Quantification of tumor angiogenesis. Six μm tumor frozen sections were fixed with 4% paraformaldehyde in PBS for
10 min at 4°C and washed three times with PBS. A three-step
biotin-streptavidin-horseradish peroxidase method was used for
antibody detection. After fixation, the sections were blocked with
10% rabbit serum and incubated overnight at 4°C with rat monoclonal CD31 antibody (550274, BD Biosciences). The sections
were then incubated with biotinylated rabbit anti-rat IgG (Vector
Labs) and streptavidin-HRP (Dako). Immunoreactivity was
revealed with 3,3'-diaminobenzidine. For quantitation of vessels,
CD31-positive vessels were counted in 8–10 fields within the central area of each tumor using a 20x objective lens and an ocular
grid (0.25 mm2 per field). The total numbers of vessel per unit
area was calculated, and the data was represented graphically.
Immunohistochemistry. Formalin-fixed paraffin-embedded
tumor sections were de-paraffinized, rehydrated and washed in
PBS. Antigen retrieval was performed in 10 mM sodium citrate,

Figure 11. CTGF drives the autophagy-senescence transition (AST) in
cancer-associated fibroblasts. Here, we show that activation of TGFβ
signaling, via CTGF expression in normal fibroblasts, is sufficient to confer the cancer-associated fibroblast phenotype. Briefly, CTGF expression
in stromal fibroblasts leads to ROS production, resulting in the stabilization of the HIF1-transcription factor. HIF1-activation then promotes the
induction of autophagy, mitophagy and glycolysis. Autophagy drives
the onset of senescence, via the autophagy-senescence transition
(AST), resulting in the upregulation of CDK-inhibitors [p21(WAF1/CIP1)
and p16(INK4A)] as well as β-galactosidase (a lysosomal enzyme and
marker of senescence). Oxidative stress, autophagy and senescence
may also contribute to CTGF-induced fibrosis and extracellular matrix
(ECM) remodeling.
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pH 6.0 for 10 min using a pressure cooker. After blocking with
3% hydrogen peroxide for 10 min, sections were incubated with
10% goat serum for 1 h. Then, sections were incubated with
primary antibodies overnight at 4°C. Antibody binding was
detected using a biotinylated secondary (Vector Labs) followed
by strepavidin-HRP (Dako). Immunoreactivity was revealed
using 3,3'-diaminobenzidine. Finally, samples were counterstained with hematoxylin, dehydrated, mounted and observed
under the microscope.
Immunofluorescence. Cells were fixed with 2% PFA for
30 min, rinsed and permeabilized with 0.1% Triton X-100,
0.2% BSA in PBS for 10 min. To quench free aldehyde groups,
cells were incubated with 25 mmol/L NH4Cl in PBS for 10 min.
Then, cells were rinsed with PBS, incubated with ATPase-IF1
antibodies, followed by fluorescently labeled secondary antibodies. Samples were incubated with DAPI, mounted and analyzed
using a confocal microscope.
Statistical analysis. Data were analyzed with the Student
t-test. p-values lower than 0.05 were considered statistically
significant.
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